h
Let’s Work Together
arrosa@select.com

Meet Arrosa, the perfect theme to elevate your online presentation with.

Search here!
Gorka Orive

Gorka Orive

Doctor of Pharmacy

Full Professor UPV/EHU. Researcher and Professor at the University Institute of Regenerative Medicine and Oral Implantology UIRMI.

Professor of Biopharmacy and Pharmacokinetics and Galenic Pharmacy (UPV/EHU) (since Feb 2011).

Positively accredited as UNIVERSITY PROFESSOR by ANECA (21/01/16). Approval of change of position to Full Professor by the UPV/EHU (October 2021).

Researcher CIBER BBN NanoBioCell Group (since 2015)

Researcher and lecturer at the UIRMI University Institute (Anitua Foundation/UPVEHU) (since 2018)

4 six-year research periods approved by ANECA (Spanish National Agency for Quality Assurance and Accreditation).

20 years of activity as a university lecturer.Participation in scientific projects, many of which (50%) as Principal Investigator.

324 international publications, 45 national publications, 25 book chapters, 3 edited books.H-index of 73, >19,550 citations.

Direction of 14 doctoral theses (7 more in progress)
>300 events and conferences, many of them with invited lectures or keynote lectures.

In the “Top Scientific Rankings” (Stanford University), he tops the list of the most influential Spanish researchers in the world in Pharmacy and Pharmacology, and is among the top 30 scientists in the world in this category, considering active researchers whose first article is in the 21st century.

Scientific Advisor to BTI Biotechnology Institute, Roche, GSK, CDI and Capcel Biologics. Founder and CSO of the biotech company Geroa Diagnostics. Founder of the company Oniria.

Extensive experience as a scientific communicator, with great presence and impact during the COVID19 pandemic.

Reviewer for different organisations, with the ERC Advanced Grant panel standing out. Several national and international awards for his research career, scientific dissemination and innovation.

Courses taught

Published Articles

The increasing prevalence of tissue injuries is fueling the development of autologous biological treatments for regenerative medicine. Here, we investigated the potential of three different bioinks based on the combination of gelatin and alginate (GA), enriched in either hydroxyapatite (GAHA) or hydroxyapatite and PRGF (GAHAP), as a favorable microenvironment for human dental pulp stem cells (DPSCs)

  • Author:
  • Eduardo Anitua
  • Gorka Orive
  • Miriam Idoipe
  • Borja de la Sen-Corcuera
  • Ronald M Sánchez-Ávila
  • Carmen Sánchez-Pérez
  • María Satué
  • Antonio Sánchez-Pérez
  • Francisco Muruzabal
  • Luis Pablo

This prospective and comparative study aimed to compare the use of a conjunctival autograft (CAG), plasma rich in growth factors fibrin membrane (mPRGF) or amniotic membrane transplantation (AMT) in primary pterygium surgery.

  • Author:
  • Eduardo Anitua
  • Gorka Orive
  • Alfonso L Sabater
  • Hazem M Mousa
  • Xavier Quinones
  • Felipe Valenzuela
  • Ronald Mauricio Sanchez Avila
  • Jesús Merayo
  • Victor L Perez

To evaluate the safety and efficacy of the surgical use of autologous plasma rich in growth factors fibrin membrane (mPRGF) in improving corneal wound healing and regeneration in a variety of complex ocular surface defects.

Videos available on BTI Channel

In addition to this small sample, on BTI Channel you can increase your knowledge about oral implantology, regenerative medicine and sleep apnoea.

Gorka Orive
What makes Endoret® PRGF® unique? Pre-clinical research and differences with other blood derivatives